23 Oct 2025 | 5 Mins Read
Biocon shares rise after Canadian approval for autoimmune treatment
Flipitmoney
Biocon Biologics received approval from Health Canada for its biosimilar, Yesintek, which treats autoimmune conditions like plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Yesintek will be available via the My Biocon Biologics patient support programme. Its parent company, Biocon, saw its shares gain 0.8% on Thursday.